SUMMARY

As one of the leading institutes worldwide with expertise in areas of drug development including PI3K/akt/mTOR inhibitors, MAPK inhibitors or drugs targeting developmental pathways such as TGFbeta, SHH, WNT, and NOTCH, we have been clinically testing the best-in-class drugs. We have also expanded our expertise to other cell-signaling pathway inhibitors such as MET and FGFR, immunotherapeutics including agents targeting PD1/PDL1, OX40, CD40, and engineered antibodies.

In addition, we have performed several clinical trials with novel-novel combinations – linking the following inhibitors: PI3K with MEK, IGF-1R with PI3K or MEK, Smo with a PI3K, and NOTCH with mTOR. In immunotherapeutics, we have explored combinations such as a CXCR4 antagonist with chemotherapy or a CD40 agonist with an anti-PDL1 agent. We have conducted many clinical trials with patients selected on molecular alterations (mutations in AKT, EGFR, PIK3CA, PTEN, ALK, BRAF, NRAS, KRAS, FGFR1 and 2, MET, HER2, HER3; amplifications in HER2, AKT 1, 2, and 3, FGFR1, MET, NOTCH1-4, traslocation of RSPO2/3 and FGFR1-3, and alteration in protein expression of PTEN, or overexpression of PDL1, GCC or of prolactin receptor). Finally, our group has co-developed several molecular tests for patient screening such as disease-oriented mutation panels for Sequenom.

PUBLICATIONS